Dyax Corp. (DYAX) Announces Partnership With Taiba for Distribution of Kalbitor®(ecallantide) in the Middle East
6/5/2012 10:56:46 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) has granted exclusive distribution rights to taiba ME (taiba) for the use of Kalbitor in the treatment of hereditary angioedema (HAE) within the Middle East, including Saudi Arabia, United Arab Emirates, Oman, Bahrain, Qatar, Kuwait, Libya and Iran. Collectively, the population covered by this agreement is more than 100 million people and thus represents a significant expansion of global access to Kalbitor. Dyax and taiba will share profits on Kalbitor sales within the licensed territory.